在COVID-19大流行期间,扩大了新辅助内分泌疗法在乳腺癌早期阶段的扩大指示
Rhami Khorfan1, Halley P Vora1, Jukes P Namm1
1Surgical Oncology Division, Department of Surgery, Loma Linda University Health, Loma Linda, CA, USA.
Annals of surgical oncology
|August 12, 2024
概括
在COVID-19大流行期间,新辅助疗法在早期乳腺癌患者的使用增加,这些患者面临手术延迟. 这种转变反映了医疗保健系统的调整,需要对长期结果进行监测.
科学领域:
- 在瘤学瘤学.
- 公共卫生 公共卫生
- 医疗保健服务研究 医疗服务研究
背景情况:
- 由于COVID-19的流行,流行性乳腺癌联盟 (PBCC) 发布了乳腺癌患者的分拣建议.
- 这些指导方针建议为手术延迟的早期病例提供新辅助治疗.
- 这项研究调查了与PBCC指南一致的国家新辅助药治疗模式.
研究的目的:
- 评估乳腺癌患者使用新辅助疗法的国家趋势.
- 评估在COVID-19大流行期间遵守流行性乳腺癌联盟 (PBCC) 选建议.
- 为了确定与新辅助内分泌疗法 (NET) 使用相关的患者和医院因素.
主要方法:
- 分析了2018-2020年国家癌症数据库中的手术患者的数据.
- 2020年按照PBCC指南治疗的患者比例与2018-2019年队列进行了比较.
- 后勤回归模型评估了患者/医院因素与NET使用之间的关联.
主要成果:
- 2020年,患有cT1N0 ER+/PR+/HER2疾病的患者接受新辅助内分泌疗法 (NET) 的可能性显著增加 (OR,3.08).
- 在2020年,cT2N0或cT1N1疾病的患者中,NET的使用也增加了 (OR,1.76).
- 学术中心,黑人/亚裔种族,并发病症和特定的美国地区与更高的NET利用率有关.
结论:
- 由于COVID-19大流行,乳腺癌患者的新辅助疗法采用率增加.
- 在大流行期间,医疗保健系统的限制加速了早期乳腺癌中新辅助疗法的使用.
- 根据PBCC建议治疗的患者的长期结果需要密切观察.
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...